RxDoctor Payments Data
★ My doctorsLook up a doctor →

Gail Enyert

Family · Casper, WYNPI 1306813647

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (48.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Novartis at 49.4% of the total. Reporting peaked in 2021 at $1,227 and has fallen 96.3% since, to $45 in 2023.

$1,582in general payments, 2019–2025

Across 50 payments — averaging $31.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$781
  • Merck$121
  • Incyte Corporation$89
  • Amgen$86
  • Daiichi Sankyo Inc.$60
  • Sanofi$53
  • plus $391 from 15 others

What the payments were for

  • Food & beverage$72246%
  • Education$956%
  • Other$76548%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis9$781
Merck6$121
Incyte Corporation2$89
Amgen5$86
Daiichi Sankyo Inc.3$60
Sanofi3$53
Pharmacyclics LLC, An Abbvie Company2$49
EMD Serono, Inc.2$39
Seagen Inc.2$34
Bristol Myers Squibb2$33
E.r. Squibb & Sons, L.L.C.2$31
Eisai Inc.2$29
GSK2$27
Regeneron Healthcare Solutions, Inc.1$22
Mirati Therapeutics, Inc.1$21
Epizyme, Inc.1$20
AVEO Pharmaceuticals, Inc.1$19
AstraZeneca1$19
Rigel Pharmaceuticals, Inc.1$17
Johnson & Johnson1$17
G1 Therapeutics, Inc.1$15

How this compares

$1,582 in reported general payments places this provider in the 85th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming →

Other family in Casper

See the full list for Wyoming →

Where these figures come from

Is this you, or does something look wrong? →